58,229 Shares in Bioventus Inc. (NYSE:BVS) Purchased by Bailard Inc.

Bailard Inc. acquired a new stake in Bioventus Inc. (NYSE:BVS) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 58,229 shares of the company’s stock, valued at approximately $307,000.

Other institutional investors also recently modified their holdings of the company. Juniper Investment Company LLC increased its holdings in shares of Bioventus by 2.7% in the third quarter. Juniper Investment Company LLC now owns 6,833,857 shares of the company’s stock valued at $22,552,000 after purchasing an additional 176,870 shares in the last quarter. Kent Lake Capital LLC boosted its position in Bioventus by 15.0% in the 3rd quarter. Kent Lake Capital LLC now owns 1,035,168 shares of the company’s stock valued at $3,416,000 after buying an additional 135,168 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Bioventus by 3.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 92,293 shares of the company’s stock valued at $305,000 after buying an additional 3,434 shares during the period. Kennedy Capital Management LLC bought a new stake in shares of Bioventus during the third quarter worth $220,000. Finally, Citigroup Inc. lifted its stake in shares of Bioventus by 13,474.4% during the third quarter. Citigroup Inc. now owns 52,533 shares of the company’s stock valued at $173,000 after acquiring an additional 52,146 shares during the period. 62.94% of the stock is owned by institutional investors.

Insider Buying and Selling at Bioventus

In other news, CFO Mark Leonard Singleton sold 5,541 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $5.39, for a total transaction of $29,865.99. Following the completion of the transaction, the chief financial officer now directly owns 25,665 shares in the company, valued at approximately $138,334.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 15,720 shares of company stock valued at $80,435. 29.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum raised their price target on Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.

Bioventus Trading Down 2.2 %

BVS opened at $3.98 on Monday. Bioventus Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $6.08. The company has a market cap of $315.10 million, a price-to-earnings ratio of -1.58 and a beta of 0.50. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.53 and a quick ratio of 1.01. The firm has a 50 day simple moving average of $4.94 and a 200 day simple moving average of $4.54.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, March 12th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. Bioventus had a negative net margin of 30.49% and a positive return on equity of 2.25%. The company had revenue of $135.42 million during the quarter, compared to analysts’ expectations of $124.84 million. On average, sell-side analysts anticipate that Bioventus Inc. will post 0.16 earnings per share for the current year.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.